Search PubMed⌕ Search

Biomedical subjects

B A Torres

Publications and source records attributed to B A Torres.

At least 55 records · Page 3Linked to original sources
PubMed1988

A novel arginine vasopressin-binding peptide that blocks arginine vasopressin modulation of immune function.

We report on a novel peptide that blocks the neuroendocrine hormone arginine vasopressin (AVP) helper signal for IFN-gamma production by direct interaction with the hormone. The AVP-binding nonapeptide has the sequence Thr-Met-Lys-Val-Leu-Thr-Gly-Ser-Pro (binding peptide). AVP and its 6-amino acid N-terminus cyclic ring pressinoic acid (PA) are both capable of replacing the IL-2 requirement for IFN-gamma production by mouse splenic lymphocytes. We show that the AVP-binding peptide specifically and reversibly blocks AVP help in IFN-gamma production, but fails to block the helper signal of PA. Thus the intact AVP molecule and not just the N-terminal cyclic ring is important for interaction with the binding peptide. AVP interacts with the binding peptide with an apparent KD of approximately 50 nM. The AVP-binding peptide does not inhibit AVP interaction with its receptor on lymphocytes. Interestingly, whereas the AVP-binding peptide does not block the PA helper signal for IFN-gamma induction, the complex of AVP and binding peptide does reversibly block the PA signal. The AVP family of hormones requires conformational flexibility for signal transduction. Thus, we hypothesize that the AVP-binding peptide restricts this flexibility and converts AVP into an antagonist of its own action.

Adjuvants, Immunologic↗
PubMed1988

Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1.

Ovine trophoblast protein-1 (oTP-1) is an antiluteolytic protein which plays an important role in maternal recognition of pregnancy. It exhibits a 45-70% amino acid sequence homology with alpha interferons (IFN-alpha s) from various species. We show here that purified oTP-1 has high specific antiviral activity (2-3 X 10(8) units/mg protein) and is thus as potent as any known IFN. oTP-1 is antigenically distinct but does show antigenic relation to both ovine and bovine IFN-alpha s. The antiviral activity of oTP-1 could be demonstrated in Day 12 - Day 16 conceptus culture medium and in allantoic fluid from Day 60 of pregnancy. Our functional and antigenic characterization suggests that oTP-1 is a type of IFN-alpha which performs classic roles associated with IFN-alpha, as well as being the primary conceptus secretory product responsible for maternal recognition of pregnancy.

Allantois↗
PubMed1988

Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-gamma production. Evidence for a novel AVP receptor on mouse lymphocytes.

Arginine vasopressin (AVP), a nine-amino acid neurohypophyseal hormone, is capable of replacing the helper cell requirement for IFN-gamma production by Lyt-2+ mouse splenic lymphocytes. We present data here showing that the AVP helper signal occurs via interaction with a novel R on splenic lymphocytes and involves primarily the N-terminal six-amino acid cyclic ring (pressinoic acid) with the C-terminal three-amino acid end of AVP playing a minor role. Pressinoic acid was capable of providing help at concentrations similar to those of AVP, whereas oxytocin and isoleucine pressinoic acid were 10- and 100-fold less effective, respectively. Isoleucine pressinoic acid has the same structure as pressinoic acid except for the substitution of isoleucine for phenylalanine in position 3 of the sequence. Consistent with the function data, R binding competitions with splenic lymphocyte membrane preparations showed that AVP and pressinoic acid competed similarly with [3H]AVP, whereas oxytocin and isoleucine pressinoic acid were much less effective competitors. Further characterization of the AVP lymphocyte R was performed using AVP analogues having well defined agonist and antagonist activities on either V1 (vasopressor) R or V2 (antidiuretic) R. The AVP helper signal was blocked by the V1 antagonist [d(CH2)1(5) Tyr(methyl)]AVP but not by another V1 antagonist, [d(CH2)1(5)D-Tyr(ethyl)2Val4]AVP. Both V1-R antagonists were able to block [3H]AVP binding to the V1-R on liver cells, whereas only the V1 antagonist that blocked AVP help was able to compete effectively for the spleen AVP-R. Neither a V2 agonist nor a V2 antagonist had any effect on AVP help in IFN-gamma production. These data strongly indicate the presence of a novel AVP-R on spleen lymphocytes, which is related to the classic V1-R on liver cell membranes.

Adjuvants, Immunologic↗
PubMed1988

Use of synthetic peptides to identify an N-terminal epitope on mouse gamma interferon that may be involved in function.

We previously have assigned N-terminal specificity to three hamster monoclonal antibodies (mAbs I, II, and III) produced to mouse recombinant gamma interferon (IFN-gamma), based on the ability of the N-terminal peptide IFN-gamma-(1-39) to block binding of 125I-labeled IFN-gamma (125I-IFN-gamma) and on the ability of these antibodies to bind 125I-IFN-gamma-(1-39). Only mAb I blocked function and binding to the IFN-gamma receptor, suggesting that it may bind to a region of the molecule involved in interaction with the receptor. To further define the epitope specificities of the antibodies, a series of N-terminal peptides were synthesized and tested for their ability to block antibody binding of 125I-IFN-gamma. Peptides IFN-gamma-(1-39), IFN-gamma-(1-20), IFN-gamma-(3-20), and IFN-gamma-(5-20) inhibited binding of 125I-IFN-gamma by mAb I in order of decreasing effectiveness, while peptide IFN-gamma-(7-20) was without effect. Peptides IFN-gamma-(1-39), IFN-gamma-(1-20), and IFN-gamma-(3-20) also inhibited binding of 125I-IFN-gamma by mAb II but were less effective when compared with their inhibition of mAb I. IFN-gamma-(5-20) and IFN-gamma-(7-20) did not inhibit binding by mAb II. Peptides IFN-gamma-(1-10), IFN-gamma-(10-30), and IFN-gamma-(21-44) did not inhibit either mAb I or mAb II. While IFN-gamma-(1-39) and IFN-gamma-(10-30) inhibited binding by mAb III, neither IFN-gamma-(1-20) nor any of its truncated forms were inhibitory. All three antibodies had similar Kd values for 125I-IFN-gamma. A prediction of the secondary structure of the molecule and the peptide inhibition data suggest that the epitope (possible receptor binding region) for mAb I involves a loop in the area containing residues 12-20, with sequences N-terminal to these residues possibly stabilizing the loop conformation. Direct evidence that the N-terminal 1-39 region of IFN-gamma is important in receptor binding was the observation that IFN-gamma-(1-39), but not the C-terminal IFN-gamma-(95-133), competed with 125I-IFN-gamma for the receptor on mouse L cells. IFN-gamma-(1-39) also specifically blocked IFN-gamma antiviral activity at concentrations that blocked binding to the receptor. The fact that IFN-gamma-(1-39) was the only peptide that blocked both IFN-gamma binding to receptor and function is consistent with the antibody competition data, where it was the most effective peptide in blocking binding of 125I-IFN-gamma by the N-terminal-specific mAbs. The combination of peptide mapping of epitope specificities and receptor competition should further help define the structural basis for IFN-gamma action.

Animals↗
PubMed1988

Steric relationship of amino-terminal and carboxy-terminal domains of murine interferon-gamma as assessed by monoclonal antibodies.

Spleen cells from a hamster immunized with murine interferon-gamma (IFN-gamma) carboxy-terminal (95-133) synthetic peptide [IFN-gamma (95-133)] conjugated to keyhole limpet hemocyanin (KLH) were fused with mouse myeloma cells, resulting in the production of an anti-IFN-gamma (95-133) monoclonal antibody, which reacted with IFN-gamma. This monoclonal antibody bound [125I]IFN-gamma in a dose-dependent and reversible fashion, and neutralized the antiviral and macrophage priming activities of IFN-gamma. Antibody-antibody competition for [125I]IFN-gamma binding, using this carboxy-terminal-specific antibody and two previously described amino-terminal-specific monoclonal antibodies, indicated that the carboxy-terminal-specific monoclonal antibody competed only with itself and that the two amino-terminal-specific monoclonal antibodies similarly competed only with each other for [125I]IFN-gamma. The data suggest that the amino- and carboxy-terminal IFN-gamma domains important for function are sterically distant from one another, and suggest the intriguing possibility that interaction of IFN-gamma with its receptor may involve more than one binding site on the IFN-gamma molecule.

Animals↗
PubMed1987

Phospholipase A2 treatment of lymphocytes provides helper signal for interferon-gamma induction. Evidence for second messenger role of endogenous arachidonic acid.

To examine the role of endogenous arachidonic acid (AA) as the possible second messenger signal in interferon-gamma (IFN-gamma) production, helper cell-depleted mouse spleen cell cultures were treated with the enzyme phospholipase A2 (PLA2). Treatment with PLA2 from several different animal sources at concentrations between 10 and 300 U/ml resulted in complete, dose-dependent restoration of competence for IFN-gamma production. By comparison, phospholipase C (PLC) from several different species failed to restore competence at concentrations between 0.3 and 30 U/ml; the inability of PLC to provide the helper signal for induction of IFN-gamma was not due to cytotoxicity. Since PLA2 provides competence for IFN-gamma production by sn-2 hydrolysis, it was of interest to identify eicosanoids and other lipids released from [3H]-AA labeled cells by PLA2 and PLC. Treatment of spleen cells with PLA2, but not PLC, resulted in the appreciable release of AA only. Sufficient AA was released from spleen cells for restoration of competence for production of IFN-gamma. All glycerol-derived cell membrane phospholipids examined (phosphatidylethanolamine, -inositol, -choline, and -serine) incorporated labeled AA which was releasable by treatment with PLA2. The data support and extend previous studies which suggested that AA plays a pivotal role in mediation of the interleukin 2 helper signal for IFN-gamma production.

Animals↗
PubMed1986

Epitope and functional specificity of monoclonal antibodies to mouse interferon-gamma: the synthetic peptide approach.

Spleen cells from hamsters immunized with recombinant mouse interferon-gamma (IFN-gamma) were fused with mouse myeloma cells, resulting in the production of four anti-IFN-gamma monoclonal antibodies. Binding of 125I-IFN-gamma by these protein A-bound antibodies was specifically blocked by cold IFN-gamma. Binding by three of these antibodies was also blocked by a synthetic peptide corresponding to the N-terminal 1-39 amino acids of IFN-gamma, whereas a corresponding C-terminal (95-133) peptide had no effect on binding. The N-terminal specificity of these three antibodies was confirmed by their specific binding of 125I-N-terminal (1-39) peptide. One of the N-terminal specific monoclonal antibodies inhibited both antiviral and macrophage priming (for tumor cell killing) activities of IFN-gamma, whereas the other two had no effect on either biologic function. The selectivity of the inhibition of IFN-gamma function was not due to a differential ability of the N-terminal specific antibodies to bind IFN-gamma. Blocking experiments with cold IFN-gamma and N-terminal peptide suggest that the epitope specificities of the monoclonal antibodies could be determined by the conformational or topographic structure of IFN-gamma. An exact determination of the epitope specificity of the monoclonal antibody that inhibited IFN-gamma function could provide insight into the structural basis for the role of the N-terminal domain in the biologic function of IFN-gamma. Polyclonal antibodies to either the N-terminal or the C-terminal peptides also inhibited both the antiviral and the macrophage-priming activities of IFN-gamma. All of the antibodies that inhibited IFN-gamma function also blocked binding of IFN-gamma to membrane receptor on cells, whereas antibodies that did not block function also did not inhibit binding. The data suggest that both the N-terminal and the C-terminal domains of IFN-gamma play an important role in its antiviral and macrophage-priming functions, possibly in a cooperative manner.

Amino Acid Sequence↗
PubMed1985

Lipopolysaccharide and polyribonucleotide activation of macrophages: implications for a natural triggering signal in tumor cell killing.

There is evidence that activation of macrophages for tumor cell killing can involve either two signals (interferon/lipopolysaccharide, for example) or one signal (lipopolysaccharide or double-stranded RNA, for example). We investigated the apparent one-signal activation of bone marrow-derived macrophages for P815 mastocytoma killing by treatment with lipopolysaccharide (LPS) or by the synthetic double-stranded polyribonucleotide polyinosinic acid-polycytidylic acid (poly I:C). We found that "direct" activation of macrophages by either LPS or poly I:C was still a two-signal process. Based on antibody neutralizations, the first signal was probably mediated by LPS or poly I:C induced alpha/beta interferon in the macrophage cultures, and the second signal was that of a direct effect of the LPS or poly I:C on the cell. The fact that poly I:C can provide the triggering signal for macrophage activation suggests a possible role for double-stranded RNA structures in macrophage triggering. Such double-stranded RNA requirements could be met by single-stranded RNAs that possess significant double-strandedness in their structures.

Animals↗
PubMed1985

Mechanism of calcium ionophore A23187-induced priming of bone marrow-derived macrophages for tumor cell killing: relationship to priming by interferon.

Interferon primes macrophages for tumor cell killing by rendering them sensitive to triggering agents such as lipopolysaccharide. In an attempt to determine the nature of the priming signal, we tested phorbol 12-myristate 13-acetate, diacylglycerol, platelet-activating factor, arachidonic acid, leukotriene B4, and the calcium ionophore A23187 for their ability to prime mouse bone marrow-derived macrophages for activation to kill P815 mastocytoma target cells. The ionophore A23187 was the only substance that was able to replace the interferon priming signal. A23187 priming appeared to be due in part to induction of interferon alpha/beta in the macrophage cultures, since its effect was partially but specifically blocked by antibody to interferon alpha/beta. Consistent with this was the observation that A23187 induced interferon alpha/beta production in macrophage cultures. The fact that A23187 priming was not completely reversed by antibody to interferon would suggest that factors unrelated to interferon induction also played a role in macrophage priming. The failure of phorbol myristate acetate or diacylglycerol to prime macrophages for tumor cell killing would suggest that activation of protein kinase C is not sufficient for priming. Thus, A23187 appears to provide the priming signal for macrophage killing through the combination of interferon- and non-interferon-induced mechanisms.

Animals↗
PubMed1985

Interleukin 2-mediated events in gamma-interferon production are calcium dependent at more than one site.

Both leukotrienes and dibutyryl cyclic GMP can replace the interleukin 2 (IL 2) requirement for gamma-interferon (gamma-IFN) production. In this study, the Ca dependence of the IL 2 help was demonstrated by blockage of gamma-IFN production by the Ca blocker Mn, and the competitive reversal of this block by Ca. Neither leukotriene C4 nor dibutyryl cyclic GMP could reverse the Mn block, which suggests that arachidonic acid release from phospholipids is not the only Ca-dependent event in IL 2 help for gamma-IFN production. A role for calmodulin or protein kinase C in the IL 2-mediated events was suggested by the blockage of gamma-IFN production by chlorpromazine. Relatively high concentrations of Ca were able to replace the IL 2 helper effects. Consistent with this were Ca influx experiments that showed that IL 2 helper signals for gamma-IFN production involved activation of a Ca channel.

Animals↗
PubMed1985

Regulation of lymphokine production by arginine vasopressin and oxytocin: modulation of lymphocyte function by neurohypophyseal hormones.

The neurohypophyseal hormones arginine vasopressin (AVP) and oxytocin are capable of replacing the interleukin 2 (IL 2) requirement for T cell mitogen induction of gamma-interferon (IFN-gamma) in mouse spleen cell cultures. The structural basis for the helper signal by these hormones resides in the six N-terminal amino acids of AVP based on the relative ability of AVP, oxytocin, vasotocin, and pressinoic acid (AVP six N-terminal amino acid peptide) to help in IFN-gamma induction. AVP and pressinoic acid provide maximal help at 10(-10) M, while oxytocin and vasotocin with isoleucine at position three in place of phenylalanine are 10-fold less effective. An AVP competitive antagonist of vasopressor activity blocks the AVP helper signal for production of IFN-gamma, while having no effect on IL 2 help. This suggests that the AVP helper signal operates via binding to an AVP vasopressor-type receptor on lymphocytes.

Animals↗
PubMed1984

Enhancement of the in vitro antibody response by thyrotropin.

The pituitary hormone thyrotropin (TSH) has been shown to enhance in a dose dependent manner the in vitro antibody response. Highly purified preparations of bovine and human TSH enhanced up to 375% the number of cells producing antibody to sheep erythrocytes. TSH had to be present prior to 24-48h of the initiation of culture for enhancement of the antibody response. An analogy is discussed between TSH and B lymphocyte growth and differentiation factors.

Animals↗
PubMed1984

Regulation of lymphokine (gamma-interferon) production by corticotropin.

We have shown that corticotropin (ACTH), alpha-endorphin, and enkephalins can regulate antibody responses, which suggested a role for neuropeptides in a regulatory circuit between the immune and neuroendocrine systems. ACTH and structurally related peptides were examined here for regulation of mitogen induction of the lymphokine gamma-interferon (IFN gamma) in C57BL/6 mouse spleen cell cultures. Synthetic ACTH1-39 and a porcine pituitary extract containing ACTH activity were potent suppressors of the IFN gamma response. Synthetic ACTH1-39 suppressed the response by approximately 62% at 1 to 3 microM, whereas the porcine extract suppressed by greater than 90% at 1 to 3 microM ACTH. The greater potency of the pituitary extract was shown to be due to the presence of an additional peptide of Mr 2100 that was reactive with antibodies to the N-terminal region of ACTH (ACTH1-13), possessed potent anti-cellular activity against L cells and various transformed cells, but lacked ACTH biologic activity. The anti-cellular peptide suppressed the IFN gamma response by greater than 99% at 0.05 microM. The ACTH1-39 cleavage products, alpha-melanocyte stimulating hormone (alpha MSH; acetylated and amidated ACTH1-13), and corticotropin-like intermediate lobe peptide (CLIP; ACTH18-39) had no effect on IFN gamma production. ACTH1-24, like ACTH1-39, has full steroidogenesis activity but also had no effect on IFN gamma production, which suggests a dissociation of the immunoregulatory and steroidogenic properties of ACTH1-39. ACTH1-39, and possibly also the anti-cellular 2100 Mr peptide, is initially synthesized as the precursor polyprotein pro-opiomelanocortin (POMC). Enzymatic processing of POMC, first to the active ACTH1-39 or the anti-cellular peptide and then to the inactive smaller peptides, probably plays an important role in regulation of lymphokine and antibody production by ACTH and ACTH-related neuropeptides. This is consistent with the recent demonstration of the production of ACTH-like peptides by lymphocytes.

Adrenocorticotropic Hormone↗
PubMed1984

Leukotrienes: positive signals for regulation of gamma-interferon production.

Leukotrienes B4, C4, and D4 were capable of replacing the helper cell or interleukin 2 requirement for gamma-interferon (IFN gamma) production by Lyt-1-,2+ cells from C57BL/6 mouse spleen cells at leukotriene concentrations as low as 0.002 microM. An antioxidant inhibitor (butylated hydroxyanisole) of lipoxygenase metabolism of arachidonic acid suppressed IFN gamma production. The suppression was significantly reversed by leukotriene C4, which further suggests that leukotrienes and possibly other substances produced by the lipoxygenase pathway of arachidonic acid metabolism play an important role in the regulation of IFN gamma production. All of these events may be related to activation of guanylate cyclase activity, since cyclic GMP also significantly reversed the suppressor effects of butylated hydroxyanisole in IFN gamma production. The leukotriene help for IFN gamma production was independent of DNA synthesis or cellular proliferation. The data are consistent with the hypothesis that lipxoygenase products of arachidonic acid metabolism may play a role in the mediation of interleukin 2 help in IFN gamma production. Cells that are rich sources of leukotrienes, then, should play important roles in positive regulation of lymphokine production.

Animals↗